These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 547122)

  • 21. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine.
    Matsuoka N; Aigner TG
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1201-9. PubMed ID: 9067304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute effect of drugs upon memory of patients with senile dementia.
    Delwaide PJ; Devoitille JM; Ylieff M
    Acta Psychiatr Belg; 1980; 80(5):748-54. PubMed ID: 7234458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FR121196, a potential antidementia drug, ameliorates the impaired memory of rat in the Morris water maze.
    Yamazaki M; Matsuoka N; Maeda N; Kuratani K; Ohkubo Y; Yamaguchi I
    J Pharmacol Exp Ther; 1995 Jan; 272(1):256-63. PubMed ID: 7815340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Planning abilities and chess: a comparison of chess and non-chess players on the Tower of London task.
    Unterrainer JM; Kaller CP; Halsband U; Rahm B
    Br J Psychol; 2006 Aug; 97(Pt 3):299-311. PubMed ID: 16848944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of physostigmine and scopolamine on memory for food caches in the black-capped chickadee.
    Mineau P; Boag PT; Beninger RJ
    Pharmacol Biochem Behav; 1994 Oct; 49(2):363-70. PubMed ID: 7824551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of physostigmine and scopolamine on rats' performances in object-recognition and radial-maze tests.
    Ennaceur A; Meliani K
    Psychopharmacology (Berl); 1992; 109(3):321-30. PubMed ID: 1365633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholinergic mechanisms and alterations in behavioral suppression as factors producing time-dependent changes in avoidance performance.
    Anisman H
    J Comp Physiol Psychol; 1973 Jun; 83(3):465-77. PubMed ID: 4715307
    [No Abstract]   [Full Text] [Related]  

  • 28. Physostigmine challenge before and after chronic cholinergic blockade in elderly volunteers.
    Dukoff R; Wilkinson CW; Lasser R; Friz J; Conway A; Bahro M; Peskind ER; Sunderland T
    Biol Psychiatry; 1999 Jul; 46(2):189-95. PubMed ID: 10418693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects.
    Rupniak NM; Steventon MJ; Field MJ; Jennings CA; Iversen SD
    Psychopharmacology (Berl); 1989; 99(2):189-95. PubMed ID: 2508153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of pesticides and drugs on working memory in rats: continuous delayed response.
    Heise GA; Hudson JD
    Pharmacol Biochem Behav; 1985 Oct; 23(4):591-8. PubMed ID: 3934688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine.
    Meshulam Y; Cohen G; Chapman S; Alkalai D; Levy A
    J Appl Toxicol; 2001 Dec; 21 Suppl 1():S75-8. PubMed ID: 11920924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine.
    Bartus RT
    Pharmacol Biochem Behav; 1978 Dec; 9(6):833-6. PubMed ID: 106402
    [No Abstract]   [Full Text] [Related]  

  • 33. Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine.
    Preston GC; Ward C; Lines CR; Poppleton P; Haigh JR; Traub M
    Psychopharmacology (Berl); 1989; 98(4):487-94. PubMed ID: 2570433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats.
    Murray TK; Cross AJ; Green AR
    Psychopharmacology (Berl); 1991; 105(1):134-6. PubMed ID: 1745706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scopolamine reversal of tremor produced by low doses of physostigmine in rats: evidence for a cholinergic mechanism.
    Stanford JA; Fowler SC
    Neurosci Lett; 1997 Apr; 225(3):157-60. PubMed ID: 9147394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of physostigmine on relative acetylcholine output induced by systemic treatment with scopolamine in in vivo microdialysis of rat frontal cortex.
    Liu JK; Kato T
    Neurochem Int; 1994 Jun; 24(6):589-96. PubMed ID: 7981642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human memory and the cholinergic system. A relationship to aging?
    Drachman DA; Leavitt J
    Arch Neurol; 1974 Feb; 30(2):113-21. PubMed ID: 4359364
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral physostigmine and impaired memory in adults with brain injury.
    Cardenas DD; McLean A; Farrell-Roberts L; Baker L; Brooke M; Haselkorn J
    Brain Inj; 1994 Oct; 8(7):579-87. PubMed ID: 7804294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time dependent changes in anterograde scopolamine-induced amnesia in rats.
    Moss DE; Rogers JB; Deutsch JA; Salome RR
    Pharmacol Biochem Behav; 1981 Mar; 14(3):321-3. PubMed ID: 7232457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term memory: facilitation and disruption with cholinergic agents.
    Alpern HP; Marriott JG
    Physiol Behav; 1973 Oct; 11(4):571-5. PubMed ID: 4743228
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.